Takeda Pharmaceutical FY23 Core EPS ¥484 Down From ¥558 YoY, Sales ¥4.263T Up From ¥4.027T YoY
Portfolio Pulse from Benzinga Newsdesk
Takeda Pharmaceutical reported a decrease in FY23 core EPS to ¥484 from ¥558 year-over-year, while sales increased to ¥4.263 trillion from ¥4.027 trillion.
May 09, 2024 | 6:34 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Takeda Pharmaceutical's FY23 report shows a decrease in core EPS but an increase in sales compared to the previous year.
The mixed results with a decrease in EPS but an increase in sales could lead to a neutral short-term impact on Takeda's stock price. Investors may view the sales growth positively, but the decline in profitability could raise concerns.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100